+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Lung Cancer Diagnostics Market (2023-2028) by Type, Test, End-Users, and Geography, Competitive Analysis, Impact of Covid-19, Impact of Economic Slowdown & Impending Recession with Ansoff Analysis

  • PDF Icon

    Report

  • 193 Pages
  • January 2023
  • Region: Global
  • Infogence Global Research
  • ID: 5748966

People who have never smoked account for 20% of lung cancer diagnoses every year

The Global Lung Cancer Diagnostics Market is estimated to be USD 3.43 Bn in 2023 and is expected to reach USD 5.53 Bn by 2028, growing at a CAGR of 10.03%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

The Global Lung Cancer Diagnostics Market is segmented based on Type, Test, End-Users, and Geography.
  • By Type, the market is classified into Small Cell Lung Cancer and Non-small Cell Lung Cancer.
  • By Test, the market is classified into Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Blood Test, and Others.
  • By End-Users, the market is classified into Hospital Associated Laboratories, Independent Diagnostic Laboratories, and Cancer Research Institutes.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Illumina, Inc., Merck KGaA, NanoEnTek, Inc., PerkinElmer, Inc., Qiagen N.V., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Lung Cancer Diagnostics Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The analyst analyses the Global Lung Cancer Diagnostics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Lung Cancer Diagnostics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of economic slowdown & impending recession on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Lung Cancer Diagnostics Market

What is the estimated value of the Global Lung Cancer Diagnostics Market?

The Global Lung Cancer Diagnostics Market was estimated to be valued at $3.43 Billion in 2023.

What is the growth rate of the Global Lung Cancer Diagnostics Market?

The growth rate of the Global Lung Cancer Diagnostics Market is 10.0%, with an estimated value of $5.53 Billion by 2028.

What is the forecasted size of the Global Lung Cancer Diagnostics Market?

The Global Lung Cancer Diagnostics Market is estimated to be worth $5.53 Billion by 2028.

Who are the key companies in the Global Lung Cancer Diagnostics Market?

Key companies in the Global Lung Cancer Diagnostics Market include Abbott Laboratories, ACON Laboratories Inc., Agilent Technologies, Inc., bioMérieux SA, Bio, Rad Laboratories, Inc., Boehringer Ingelheim GmbH, Danaher Corp., Eli Lilly & Co. and F. Hoffmann.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders

2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study

3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook

4 Market Dynamics
4.1 Drivers
4.1.1 Rising Cases and Incidences of Lung Cancer with Increase in the Number of Smokers
4.1.2 Growing Number of Private Diagnostics Centers
4.1.3 Increasing Initiatives by Government and Private Organizations
4.2 Restraints
4.2.1 High Cost Associated with Diagnostic Imaging System
4.3 Opportunities
4.3.1 Ongoing Research Activities in the Cancer Diagnosis Systems
4.3.2 Technological Advancement in Diagnosis Systems
4.4 Challenges
4.4.1 Lack of Adoption of Lung Cancer Screening

5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Impact of Economic Slowdown & Impending Recession
5.6 Ansoff Matrix Analysis

6 Global Lung Cancer Diagnostics Market, By Type
6.1 Introduction
6.2 Small Cell Lung Cancer
6.3 Non-Small Cell Lung Cancer

7 Global Lung Cancer Diagnostics Market, By Test
7.1 Introduction
7.2 Imaging Test
7.3 Biopsy
7.4 Sputum Cytology
7.5 Molecular Test
7.6 Blood Test
7.7 Others

8 Global Lung Cancer Diagnostics Market, By End-Users
8.1 Introduction
8.2 Hospital Associated Laboratories
8.3 Independent Diagnostic Laboratories
8.4 Cancer Research Institutes

9 Americas' Lung Cancer Diagnostics Market
9.1 Introduction
9.2 Argentina
9.3 Brazil
9.4 Canada
9.5 Chile
9.6 Colombia
9.7 Mexico
9.8 Peru
9.9 United States
9.10 Rest of Americas

10 Europe's Lung Cancer Diagnostics Market
10.1 Introduction
10.2 Austria
10.3 Belgium
10.4 Denmark
10.5 Finland
10.6 France
10.7 Germany
10.8 Italy
10.9 Netherlands
10.10 Norway
10.11 Poland
10.12 Russia
10.13 Spain
10.14 Sweden
10.15 Switzerland
10.16 United Kingdom
10.17 Rest of Europe

11 Middle East and Africa's Lung Cancer Diagnostics Market
11.1 Introduction
11.2 Egypt
11.3 Israel
11.4 Qatar
11.5 Saudi Arabia
11.6 South Africa
11.7 United Arab Emirates
11.8 Rest of MEA

12 APAC's Lung Cancer Diagnostics Market
12.1 Introduction
12.2 Australia
12.3 Bangladesh
12.4 China
12.5 India
12.6 Indonesia
12.7 Japan
12.8 Malaysia
12.9 Philippines
12.10 Singapore
12.11 South Korea
12.12 Sri Lanka
12.13 Thailand
12.14 Taiwan
12.15 Rest of Asia-Pacific

13 Competitive Landscape
13.1 Competitive Quadrant
13.2 Market Share Analysis
13.3 Strategic Initiatives
13.3.1 M&A and Investments
13.3.2 Partnerships and Collaborations
13.3.3 Product Developments and Improvements

14 Company Profiles
14.1 Abbott Laboratories
14.2 ACON Laboratories Inc.
14.3 Agilent Technologies, Inc.
14.4 bioMérieux SA
14.5 Bio-Rad Laboratories, Inc.
14.6 Boehringer Ingelheim GmbH
14.7 Danaher Corp.
14.8 Eli Lilly & Co.
14.9 F. Hoffmann-La Roche Ltd.
14.10 Genentech, Inc.
14.11 Grifols, SA
14.12 GSK PLC
14.13 Illumina, Inc.
14.14 Merck KGaA
14.15 NanoEnTek, Inc.
14.16 PerkinElmer, Inc.
14.17 Qiagen N.V.
14.18 Quidel Corp.
14.19 Sanofi SA
14.20 Sysmex Corp.
14.21 Thermo Fisher Scientific, Inc.

15 Appendix
15.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • ACON Laboratories Inc.
  • Agilent Technologies, Inc.
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim GmbH
  • Danaher Corp.
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Grifols, SA
  • GSK PLC
  • Illumina, Inc.
  • Merck KGaA
  • NanoEnTek, Inc.
  • PerkinElmer, Inc.
  • Qiagen N.V.
  • Quidel Corp.
  • Sanofi SA
  • Sysmex Corp.
  • Thermo Fisher Scientific, Inc.